Because zinc deficiency induces depression and anxiety-like behavior in rodents, we examined the effects of zinc administration in several tests by measuring anxiolytic activity in mice and rats. We now report that zinc significantly increased the number of entries into the open arms in the elevated plus maze in rats. Moreover, zinc treatment significantly increased the number of punished crossings in the four-plate test and attenuated stress-induced hyperthermia (SIH) in mice. However, no effect of zinc administration was observed in the elevated plus maze test in mice. This lack of effect in the latter case was probably due to the substantial zinc-induced reduction in locomotor activity by the doses used in mice.The present data demonstrate for the first time the anxiolytic-like activity of zinc in rodents and may indicate that zinc could be used as a novel therapeutic/adjunct agent in anxiolytic therapy.
Introduction

Zinc (Zn
2+
) ions rank among the most abundant trace elements in the body. They regulate the function of numerous structural, transcriptional and enzymatic proteins that play important roles in brain function [4, 7, 22] . A substantial fraction of zinc ions is located inside synaptic vesicles of glutamatergic terminals and is released in a calcium-dependent manner [1] . Moreover, Zn 2+ is co-released with glutamate [33] , inhibits the glutamate ionotropic N-methyl-D-aspartate (NMDA) receptor complex [3] and inhibits GABA A receptors [21] . The highest levels of zinc in the central nervous system (CNS) are present in areas known to be important in depression and anxiety, including the cerebral cortical regions, the hippocampus, most amygdaloid nuclei and the lateral septum [4] . Zinc deprivation influences brain zinc homeostasis and leads to alteration in behavior, learning, mental function and susceptibility to epileptic convulsions [22, 30] . Several studies have indicated that zinc is in-volved in the pathophysiology of depression and in the mechanism of action of antidepressants [5, 11, 12, 16] . Preclinical investigations have shown that zinc produces antidepressant-like effects in animal tests (i.e., the forced swim test and the tail suspension test) and in models of depression (i.e., olfactory bulbectomy, chronic unpredictable stress and chronic mild stress) [6, 9, 15 , for review 14, 20, 24] . There are also some clinical data showing that zinc supplementation may enhance antidepressant therapy in patients with unipolar depression [13, 23] . Moreover, some preclinical data indicate a correlation between zinc deficiency and an increase in anxiety-like behavior in animal tests of anxiety, i.e., the open field test and the plus maze test in rats and the novelty suppressed feeding test in mice [31, 34] .
In the present study, we have investigated the effect of acute administration of zinc in the following anxiety tests: the elevated plus maze test in mice and rats, the four-plate test in mice and the stress-induced hyperthermia (SIH) test in mice.
Materials and Methods
Animals and drug treatment
All procedures were conducted according to the NIH Animal Care and Use Committee Guidelines and were approved by the Ethical Committee of the Institute of Pharmacology, Polish Academy of Sciences, Collegium Medicum Jagiellonian University in Krakow, and Medical University of Lublin.
The experiments were performed on male Wistar rats (220-280 g) and male albino Swiss mice (22-26 g ). The animals were kept under a natural day/night cycle at room temperature (21-23°C), with free access to food and water. Each experimental group consisted of 6-15 animals. Experiments were conducted between 9:00 a.m. and 2:00 p.m. by an observer who was blinded to the treatment.
Zinc hydroaspartate (Farmapol, Poznañ, Poland) dissolved in aqua pro injectione or vehicle (control) was administered intraperitoneally (ip) in a volume of 2 ml/kg or 10 ml/kg to rats or mice, respectively, 45 min before the test. These doses were selected based on previous behavioral data [9, 13] .
Elevated plus maze test in rats
The testing procedure was based on a method described by Pellow and File [18] . The plus maze apparatus (an automated device produced by Kinder Scientific) was made of durable, high-density, non-porous black plastic, was elevated to a height of 50 cm and consisted of two open arms (50 × 10 cm) and two closed arms (50 × 10 cm with 30-cm-high walls), which were arranged so that the two arms of each type were opposite each other. The floor of the plus maze was made of infrared-transparent material; no sensors were visible to the mice. The plus maze was placed in a darkened room, and the center of the apparatus was illuminated with a 25 W electric bulb hanging 100 cm above the maze. The plus maze apparatus was connected to PC software by a control chassis. Each rat was gently placed in the center of the plus maze, facing one of the closed arms, immediately after a 5-min adaptation period in a black plastic box (60 × 60 × 35 cm). During a 5-min test period, the automated Kinder Scientific Motor Monitor System recorded the number of entries into the closed and open arms, the time spent in each and the distance (cm) covered by a rat in each type of arm. After each trial, the maze was wiped clean.
Exploratory activity measured in the elevated plus maze in rats
The experiment was performed using a plus maze apparatus (an automated device produced by Kinder Scientific) (see above). During a 5-min test period (i.e., the time equal to the observation period in the elevated plus maze), the automated Kinder Scientific Motor Monitor System recorded the total time spent in the open and closed arms, the total entries, the total distance and X and Y ambulation; changes in these parameters would indicate that treatment with zinc affected general locomotor activity rather than anxietylike behavior specifically. After each trial, the maze was wiped clean.
Four-plates test
A single mouse was placed gently onto the plate, and each animal was allowed to explore for 15 s. After this time, each time a mouse passed from one plate to another, the experimenter electrified the whole floor for 0.5 s (current intensity 0.8 mA), which evoked a visible flight reaction from the animal. If the animal continued running, it received no new shock for the following 3 s. The number of punished crossings was counted for 60 s [2] .
Modified stress-induced hyperthermia (SIH) test in singly-housed mice
The procedure for the modified stress-induced hyperthermia test was adapted from Van der Heyden et al. [32] . For this assay, body temperature was measured in each mouse at t = 0 min (T 1 ) and t = 15 min (T 2 ). Albino Swiss mice were placed into a new cage immediately following measurement of T 1 , with the difference in temperature (T 2 -T 1 ) used as a measure of stressinduced hyperthermia. Pilot studies by Spooren et al. [25] demonstrated that a T 2 -T 1 interval of 15 min is optimal for the measurement of SIH. A comparison between T 1 in vehicle-treated mice and T 1 in testcompound-treated mice was used to determine whether the agent alone affects body temperature. Rectal temperature was measured to the nearest 0.1°C by an Ellab thermometer. The lubricated thermistor probe (2 mm diameter) was inserted 20 mm into the rectum. The mouse was held at the base of the tail during this determination, and the thermistor probe was left in place until a constant reading was obtained (± 15 s).
Elevated plus maze test in mice
The EPM studies were conducted on mice according to the method of Lister [10] 
Locomotor activity in mice
The actimeter consisted of a cylinder (30 cm in diameter, 12 cm high, MultiServ, Lublin, Poland) equipped with two perpendicular infrared light beams located 1.5 cm above the floor. Mice were placed in the actimeter, and locomotor activity (the number of interruptions of light beams) was recorded for a period of 5 min after placing each mouse into the actimeter.
Data analysis
The data were evaluated by a one-way analysis of variance (ANOVA) followed by the Newman-Keuls Multiple Comparison test. A p value less than 0.05 was considered significant.
Results and Discussion
Preclinical and clinical evidence from the last ten years indicates that zinc is involved in the pathophysiology of depression and in the mechanism of action of antidepressants [26] [27] [28] . Its antidepressant effects have been demonstrated in a number of animal tests and models of depression and in clinical studies. Moreover, it was recently demonstrated that zinc deficiency induces depression-and anxiety-like behavior in rodents [31, 34] .
In this study, we examined for the first time the anxiolytic-like effects of acute treatment with zinc hydroaspartate in the following animal tests commonly used to predict the potential anxiolytic activity of a drug in humans: the elevated plus maze test in rats and mice, the four-plate test in mice and the stressinduced hyperthermia test in mice.
The effects of acute treatment with zinc hydroaspartate on rats in the elevated plus maze are shown in Table 1 . In this test, zinc hydroaspartate was administered at doses of 65, 32. test in rats but not in mice. The lack of an effect in mice was probably due to the substantial zinc-induced reduction in locomotor activity. The mechanism responsible for the anxiolytic action of zinc is probably related to the modulation of glutamate and/or GABA-ergic systems. Based on the results of experiments examining the mechanism of zinc antidepressant-like activity, we can speculate that the anxiolytic activity of zinc (like organic NMDA receptor antagonists, e.g., [8, 19] ) may be related to its antagonism of NMDA and/or mGluR5 glutamate receptors [17 for review]. However, zinc action through GABA-ergic or serotonergic receptors cannot be disregarded [29] . Further studies are needed to evaluate the exact mechanism(s) responsible for the anxiolytic activity of zinc.
Overall, our data show for the first time the anxiolytic-like effects of zinc hydroaspartate, as evaluated by three tests in rats and mice. These data should encourage further examination of anxiolytic zinc activity and may indicate that zinc could be used as a novel therapeutic/adjunct agent in anxiolytic therapy. 
